Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of trastuzumab rezetecan versus trastuzumab deruxtecan in HR-positive HER2-low unresectable locally recurrent or metastatic breast cancer
CTR20261077Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in breast cancer (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Progression-free survival. Started Apr 2026; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261077.